MAP2K7 and neurofibromatosis type 1: Given that this patient's mesenteric plexiform neurofibroma is associated with <i>YPEL3</i> dysfunction, she is unlikely to benefit from MEK inhibitors, which are the newly approved treatment for inoperable plexiform neurofibroma in patients with neurofibromatosis type 1.